Financials
Financial year 2025
Xper Research from Oudenaarde, company number BE0803514247, closed financial year 2025 with a result of € 275,812 after tax. For that financial year Xper Research recorded a gross margin of € 1.3 million and equity of € 462,336. Compared with financial year 2024, the result moved from € 183,524 to € 275,812. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 27, 2026.
€ 462,336
▲ 148% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 275,812
▲ 50% vs 2024
Profit after tax over the fiscal year.
€ 332,837
▲ 21% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 459,336.
People and assets in 2025
9.7
Average over the fiscal year, from the social balance sheet.
€ 855,841
▲ 204% vs 2024
€ 88,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 260,090
▲ 124% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 288,992
▲ 224% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 528,601 | € 1,251,408 | ▲ 137% |
| Profit after taxes | € 183,524 | € 275,812 | ▲ 50% |
| Equity | € 186,524 | € 462,336 | ▲ 148% |
| Total debts | € 206,569 | € 646,545 | ▲ 213% |
| Cash | € 274,985 | € 332,837 | ▲ 21% |
| Retained profit | € 183,524 | € 459,336 | ▲ 150% |
| Balance sheet total | € 393,093 | € 1,108,881 | ▲ 182% |
| Employees (FTE) | - | 9.7 |
Key figures of Xper Research, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Xper Research?
What happened at Xper Research in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 275,812 (▲ 50% vs 2024). Source: NBB ↗
- Eelen Clinical Consulting became a director. NBB
- FICC became a director. NBB
- Pieters Clinical Consulting became a director. NBB
- New establishment in Oudenaarde. KBO
- Jannie Consulting became a director. NBB
- Git Consulting became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 183,524 profit in 2024 to € 275,812 profit in 2025.
Paid € 154,295 in corporate taxes since 2024.
Best year ever: 2025, with € 275,812 profit.
On average € 129,000 of value added per employee in 2025.
A new publication or filing at Xper Research? We notify you, reason included.
Follow Xper ResearchDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Xper Research are Jannie Consulting, Eelen Clinical Consulting, FICC, Git Consulting and Pieters Clinical Consulting. It owns 100% of Lorentis BV and 70% of Kando Research BV itself.
Directors
According to the 2025 annual accounts
Director · represented by Anneleen De Cock
since 2023
Director · represented by Jan Eelen
Also active at: QbD Clinical Holding, Lindexer
since 2025
Director · represented by Christof Debèfve
since 2025
Director · represented by Gita Boutmans
since 2023
Director · represented by Magdaleen Pieters
since 2025
Establishments
Establishment units
Physical locations of this company
Keirestraat 14
9700 Oudenaarde
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0803.514.247
- VAT number
- BE 0803.514.247
- Registered office
- Keirestraat 14, 9700 Oudenaarde
- Names & denominations
- Xper Research
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 July 2023
- Peppol
- Active · Active since 9 Jan 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten